US Patent

US8552002 — Compounds and compositions as protein kinase inhibitors

Composition of Matter · Assigned to IRM LLC · Expires 2029-08-25 · 3y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of formula (I) and their use as protein kinase inhibitors in treating diseases that respond to protein kinase inhibition.

USPTO Abstract

The invention relates to compounds of formula (I) wherein the substituents X 1 , R 1 , R 2 , R 3 and R 4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Drugs covered by this patent

Patent Metadata

Patent number
US8552002
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-08-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.